قالب وردپرس درنا توس
Home / Business / Regeneron stated that IDMC recommends to stop registration of some REGN-COV2 trials due to safety risks

Regeneron stated that IDMC recommends to stop registration of some REGN-COV2 trials due to safety risks



Regeneron Pharmaceuticals Inc. stock,
-2.20%
The biotech company said that after the Independent Data Monitoring Committee (IDMC) of the REGN-COV2 antibody cocktail therapy trial for COVID-19 recommended “modifications” to the patient trial, the biotech company announced Friday that it would drop its stock price. By 1.2%. Set aside. REGN-COV2 is one of the treatments prescribed by President Trump after he tested positive for COVID-19. Based on “current potential safety signals and unfavorable risks/benefits”

;, IDMC recommends suspending further enrollment of patients who require high-flow oxygen or mechanical ventilation to wait for further data analysis. IDMC also recommends continuing to recruit patients who do not require or low-flow oxygen, and continuing unmodified outpatient trials. The US Food and Drug Administration is currently evaluating whether REGN-COV2 has a potential emergency use authorization and can be used for mild to moderate outpatients with a higher risk of adverse consequences. In the past three months, the stock has fallen 13%, and the S&P 500 SPX,
-1.21%
An increase of 1.6%.


Source link